TALENT: neoadjuvant Tdxd in HER2-low, HR+ early breast cancer - modest activity, pCR ~7%, not improved by adding anastrozole or sequencing chemotherapy. A useful reminder that HER2

Carmen Criscitiello· @CarmenCriscit · X·2026-10-23 20:12· 2 days agoScore70

Body · original

TALENT: neoadjuvant Tdxd in HER2-low, HR+ early breast cancer - modest activity, pCR ~7%, not improved by adding anastrozole or sequencing chemotherapy. A useful reminder that HER2-low is not the same as HER2-driven in the curative setting. #ESMO26 #ESMOAmbassadors @myESMO

201 views · 7 likes · 2 reposts · 0 replies

Conference abstracts

LBA23matched by Proffered paper 1: Breast cancer, early and advanced stage

Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer

https://esmocongress.esmo.org

Source: Carmen Criscitiello · x.com